Therapeutic evaluation of epstein-barr virus-encoded latent membrane protein-1 targeted DNAzyme for treating of nasopharyngeal carcinomas

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 371-377

  Cao, Ya ^a   Yang, Lifang ^a   Jiang, Wuzhong ^b   Wang, Xiaoyi ^b   Liao, Weihua ^b   Tan, Guolin ^a   Liao, Yuping ^b   Qiu, Yuanzheng ^b   Feng, Deyun ^b   Tang, Faqing ^b   Hou, Bob L ^c   Zhang, Ling ^b   Fu, Jia ^b   He, Fengjiao ^b   Liu, Xiaoyu ^b   Jiang, Wenjuan ^b   Yang, Tubao ^a   Sun, Lun Quan ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; LATENT MEMBRANE PROTEIN 1; SODIUM CHLORIDE; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEMBRANE PERMEABILITY; MICROVASCULARIZATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; ADJUVANT THERAPY; ADULT; ANIMAL; DISEASE MODEL; DRUG SCREENING; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETICS; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; REPORTER GENE; TUMOR CELL LINE; VIROLOGY;

HUMAN HERPESVIRUS 4;

ADULT; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA, CATALYTIC; DNA, VIRAL; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENES, REPORTER; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895906910     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.257     Document Type: Article

References (40)

1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E and Forman, D (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Young, LS and Rickinson, AB (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
3. Lo, KW and Huang, DP (2002). Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12: 451-462.
4. Pattle, SB and Farrell, PJ (2006). The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 6: 1193-1205.
5. Morris, MA, Dawson, CW and Young, LS (2009). Role of the Epstein-Barr virusencoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 5: 811-825.
6. Li, HP and Chang, YS (2003). Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 10: 490-504.
7. Tsao, SW, Tramoutanis, G, Dawson, CW, Lo, AK and Huang, DP (2002). The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 12: 473-487.
8. Shair, KH, Bendt, KM, Edwards, RH, Bedford, EC, Nielsen, JN and Raab-Traub, N (2007). EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog 3: e166.
9. Gires, O, Kohlhuber, F, Kilger, E, Baumann, M, Kieser, A, Kaiser, C et al. (1999). Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18: 3064-3073.
10. Eliopoulos, AG, Gallagher, NJ, Blake, SM, Dawson, CW and Young, LS (1999). Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274: 16085-16096.
11. Kieser, A, Kilger, E, Gires, O, Ueffing, M, Kolch, W and Hammerschmidt, W (1997). Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 16: 6478-6485.
12. Zhao, Y, Wang, Y, Zeng, S and Hu, X (2012). LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J Clin Pathol 65: 41-45.
13. Zheng, H, Li, LL, Hu, DS, Deng, XY and Cao, Y (2007). Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 4: 185-196.
14. Abdulkarim, B, Sabri, S, Zelenika, D, Deutsch, E, Frascogna, V, Klijanienko, J et al. (2003). Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 22: 2260-2271.
15. Kenney, JL, Guinness, ME, Curiel, T and Lacy, J (1998). Antisense to the epsteinbarr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 92: 1721-1727.
16. Mei, YP, Zhou, JM, Wang, Y, Huang, H, Deng, R, Feng, GK et al. (2007). Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6: 1379-1385.
17. Li, X, Liu, X, Li, CY, Ding, Y, Chau, D, Li, G et al. (2006). Recombinant adenoassociated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-1. Int J Oncol 29: 595-603.
18. Lee, AW, Sze, WM, Au, JS, Leung, SF, Leung, TW, Chua, DT et al. (2005). Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116.
19. Santoro, SW and Joyce, GF (1997). A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 94: 4262-4266.
20. Zhang, L, Yang, L, Li, JJ and Sun, L (2012). Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy. Cancer Lett 323: 1-10.
21. Bhindi, R, Fahmy, RG, Lowe, HC, Chesterman, CN, Dass, CR, Cairns, MJ et al. (2007). Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol 171: 1079-1088.
22. Lu, ZX, Ye, M, Yan, GR, Li, Q, Tang, M, Lee, LM et al. (2005). Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther 12: 647-654.
23. Wang, Z, Luo, F, Li, L, Yang, L, Hu, D, Ma, X et al. (2010). STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur J Cancer 46: 2996-3006.
24. Lu, ZX, Ma, XQ, Yang, LF, Wang, ZL, Zeng, L, Li, ZJ et al. (2008). DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett 265: 226-238.
25. Ma, X, Yang, L, Xiao, L, Tang, M, Liu, L, Li, Z et al. (2011). Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-?B regulated ATM expression. PLoS ONE 6: e24647.
26. Yu, RZ, Zhang, H, Geary, RS, Graham, M, Masarjian, L, Lemonidis, K et al. (2001). Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 296: 388-395.
27. Vrzalikova, K, Vockerodt, M, Leonard, S, Bell, A, Wei, W, Schrader, A et al. (2011). Down-regulation of BLIMP1a by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 117: 5907-5917.
28. Ahsan, N, Kanda, T, Nagashima, K and Takada, K (2005). Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J Virol 79: 4415-4424.
29. Lin, JC, Wang, WY, Chen, KY, Wei, YH, Liang, WM, Jan, JS et al. (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470.
30. Padhani, AR and Leach, MO (2005). Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30: 324-341.
31. Cheng, HL (2007). Dynamic contrast-enhanced MRI in oncology drug development. Curr Clin Pharmacol 2: 111-122.
32. Zhang, G, Dass, CR, Sumithran, E, Di Girolamo, N, Sun, LQ and Khachigian, LM (2004). Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96: 683-696.
33. Fahmy, RG, Dass, CR, Sun, LQ, Chesterman, CN and Khachigian, LM (2003). Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9: 1026-1032.
34. Cairns, MJ, Hopkins, TM, Witherington, C, Wang, L and Sun, LQ (1999). Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 17: 480-486.
35. Cross, D and Burmester, JK (2006). Gene therapy for cancer treatment: past, present and future. Clin Med Res 4: 218-227.
36. Lai, SY, Koppikar, P, Thomas, SM, Childs, EE, Egloff, AM, Seethala, RR et al. (2009). Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 27: 1235-1242.
37. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
38. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
39. Daldrup-Link, HE, Rydland, J, Helbich, TH, Bjørnerud, A, Turetschek, K, Kvistad, KA et al. (2003). Quantification of breast tumor microvascular permeability with ferugloseenhanced MR imaging: initial phase II multicenter trial. Radiology 229: 885-892.
40. Murase, K (2004). Efficient method for calculating kinetic parameters using T1- weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 51: 858-862.